It was developed to treat cancers, such as breast and prostate cancers, with a high prevalence of PI3K/AKT pathway activation, promoting tumor survival, proliferation, growth and changes in cellular metabolic pathways [4, 5]. This evidence concerns the gene AKT1 and cancer.